43 results about "Cardiomyocyte apoptosis" patented technology

The invention discloses two bromophenol compounds and a pharmaceutical application of their pharmaceutically-acceptable salts, specifically an application in the preparation of a myocardial ischemia-reperfusion injury protection drug. The two compounds and their pharmaceutically-acceptable salts can protect cardiomyocytes during rat heart acute ischemia so as to make rat heart functions complete.After routine intravenous administration, SOD activity after myocardial ischemia-reperfusion is raised, myocardial compliance is improved, serum LDH, serum CK, serum cTnT and MDA level after myocardial ischemia-reperfusion is remarkably reduced, myocardial injury is minimized, and FasmRNA after myocardial ischemia-reperfusion can be remarkably inhibited and reduced so as to inhibit cardiomyocyte apoptosis after myocardial ischemia-reperfusion. Therefore, the two bromophenol compounds and their pharmaceutically-acceptable salts have a clear myocardial ischemia-reperfusion injury protection function, thus providing a new method and means for the clinical treatment of myocardial ischemia-reperfusion injury and opening up a new direction for clinical medication.

The invention discloses miRNA-361 (micro-ribonucleic acid-361) and application of antisense nucleotide thereof, and in particular discloses application of miRNA-361 antisense nucleotide sequence in preparing a medicament for preventing and treating heart diseases and application of miRNA-361 ribonucleic acid in preparing a medicament or kit for diagnosing or prognosing heart diseases. Massive experiments prove variation of the miRNA-361 antisense nucleotide in myocardial ischemial injury and myocardium cell apoptosis and the myocardial protection effect of the miRNA-361 antisense nucleotide. The miRNA-361 antisense nucleotide has the functions of inhibiting myocardial ischemial injury and myocardium cell apoptosis, can be used as a novel drug action target, and has important meaning to prevention and treatment of myocardial fibrosis, coronary heart disease, congestive heart failure and other heart diseases caused by myocardial ischemia clinically.

The invention relates to neural stem cell microvesicles and an application thereof, which belongs to the technical fields of biological materials and application; The microvesicles provided by the present invention are derived from neural stem cells, and the microvesicles specifically express and can deliver the protein HSP-70; through experiments, the application of the neural stem cell microvesicles in preparation of a drug for treating cardiomyocyte apoptosis-induced diseases such as myocardial reperfusion injury is proved, the above application is to increase the content of HSP-70 in cardiomyocytes by delivering HSP-70 through neural stem cell-derived microvesicles, so that cardiomyocyte apoptosis can be effectively inhibited; the use of the microvesicles of the present invention for the treatment of myocardial reperfusion injury not only has the same effect as stem cell therapy, but also avoids problems such as tumor formation, immunosuppression, and low survival rate during stem cell therapy, and growth factors, non-coding RNA and other cytoprotective factors are still available to help repair and regenerate damaged cells or tissues.

The invention relates to a compound as shown in the general formula I, or its isomer, medicinal salt and solvate; the invention also relates to a composition containing the compound as shown in the general formula I or its isomer, medicinal salt and solvate as well as a pharmaceutically acceptable carrier, excipient or diluent; the invention also relates to the usage of the compound as shown in the general formula I, or its isomer, medicinal salt and solvate in resisting cell apoptosis and preventing or treating diseases or symptoms related with cell apoptosis, especially to the usage in protecting cardiomyocytes and preventing or treating diseases or symptoms related with cardiomyocyte apoptosis.

The invention relates to the technical field of biomedicine, in particular to application of circUTRN in preparation of a medicine for treating heart failure, a recombinant vector and the medicine for treating heart failure. Experiments prove that the medicine for treating heart failure prepared from circUTRN can treat or improve heart failure, and especially has a good treatment effect on heart failure caused by ischemia reperfusion injury; specifically, the circUTRN has the effect of improving cardiac systolic insufficiency caused by myocardial ischemia reperfusion injury for 3 weeks; in addition, the circUTRN can also reduce the infarction area of the acute myocardial ischemia reperfusion injury; overexpression of the circUTRN can inhibit myocardial cell apoptosis induced by oxygen-glucose deprivation/recovery.

The present invention relates to a compound of Formula (I), or an isomer, pharmaceutically acceptable salt and solvate thereof; the present invention further relates to a pharmaceutical composition, which comprises the compound of Formula (I), or isomer, pharmaceutically acceptable salt or solvate thereof, and a pharmaceutically acceptable carrier, excipient or diluents; the present invention further relates to the use of the compound of Formula (I), or isomer, pharmaceutically acceptable salt or solvate thereof, for anti-apoptosis, prophylaxis or treatment of a disease or symptom associated with apoptosis, especially for protecting myocardial cells, and prophylaxis or treatment of a disease or symptom associated with cardiomyocyte apoptosis.

The invention relates a medicinal composition as well as a preparation method and applications of the medicinal composition. The medicinal composition is prepared from the following medicinal materials: herba agrimoniae, radix salviae miltiorrhizae, peach kernels, lignum dalbergiae odoriferae, radix ophiopogonis, rhizoma coptidis, radix scrophulariae, cortex moutan and leeches. Herba agrimoniae and radix salviae miltiorrhizae are taken as monarch drugs, peach kernels, lignum dalbergiae odoriferae and cortex moutan are taken as ministerial drugs, radix ophiopogonis, radix scrophulariae and leeches are taken as assistant drugs, the monarch drugs, the ministerial drugs and the assistant drugs perform the corresponding roles and are also matched with each other, and thus the medicinal composition has the efficacies of clearing Ying heat and eliminating toxins, promoting blood circulation to remove meridian obstruction, and strengthening the body resistance, especially has the functions of improving the cardiac function and the myocardial pathological form, promoting the angiogenesis, inhibiting the myocardium cell apoptosis, inhibiting the inflammatory reaction, protecting the endothelial cells, and the like, and has very good curative effects in treating or preventing coronary heart disease.

The invention discloses application of an alkaloid compound Hip in preparation of a product for preventing and/or treating heart injury. Activity research is carried out on the alkaloid compound Hip, and it is verified that the alkaloid compound Hip can inhibit apoptosis induced by myocardial toxicity. The myocardial apoptosis induced by the anthracycline drug DOX is inhibited by down-regulating the expression level of p-JNK and/or Cleaved-Caspase-3, so that the myocardial toxicity is relieved, the myocardial toxicity can be prevented and/or treated. The alkaloid compound Hip can be used for preparing drugs for preventing and/or treating myocardial injury related diseases.

The invention relates to the use of a Mechano Growth Factor (MGF) polypeptide or a polynucleotide encoding an MGF polypeptide in the manufacture of a medicament for the prevention or limitation of myocardial damage in response to ischemia or mechanical overload of the heart by preventing or limiting apoptosis in the myocardium.

The invention relates to the technical field of medicine, and relates to the use of salvianolic acid A in preparing a drug for treating and/or preventing cardiomyocyte apoptosis. In particular, the use of salvianolic acid A in the preparation of a medicament for preventing or treating myocardial ischemia-reperfusion injury caused by thrombolysis, percutaneous coronary intervention or coronary artery bypass surgery and the like.